
White Papers
EMA Marketing Authorization filings 6 common mistakes to avoid
Avoid those 6 common mistakes and file a successful Marketing Authorization with the EMA.
EMA Marketing Authorization Filings
6 common mistakes to avoid

A practical guide for first-time biopharma applicants entering the EU market.
Filing for EMA marketing authorisation is complex—especially for companies navigating it for the first time. This guide explores six frequent missteps that can delay or jeopardize approval.
What you'll learn:
-
Why early engagement with EMA and local agencies is non-negotiable
-
How misunderstanding centralized procedures can derail timelines
-
What a complete, high-quality dossier should look like
-
The benefits of early Orphan/PRIME designation
-
Why planning for realistic timelines and PIP compliance is essential
Each section includes real-world examples, EMA references, and practical tips to help regulatory and strategic teams improve their chances of a smooth, successful submission.
Register to download
our guide
Discover our latest news

White Papers
5 Critical Considerations for French Market Entry
Unlock the Secrets to Success in the French Biopharma Market.

Case Studies
Fast-tracking Market Entry to France
Discover how a Pharmaceutical Company can Cut 18 months off the Standard Timeline.

Case Studies
Early Access Programs in France
Explore Proven Strategies for a Quick Market Entry in France.